Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 801–900 of 946

Drugs That Target
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch4
Faculty Opinions recommendation of A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Drapkin, R. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732806333.793545982
LCK Regulates Homologous Recombination DNA Repair and Targeting Enhances PARPi Utility in HR Proficient Ovarian CancerPreprint
Dey, G., Bharti, R., Braley, C., Alluri, R. K., Esakov, E. L., Crean-Tate, K., McCrae, K. R., Joehlin-Price, A. S., Rose, P. G., Lathia, J. D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4149951
Ovarialkarzinom: Immuntherapie, quo vadis?
Marmé, F. (2022) · Die Gynäkologie · doi:10.1007/s00129-022-04963-0
542P Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
Song, K., Ma, Y., Li, N., Bu, H., Huang, Y., Jin, C., Wen, H., Feng, S.-C., Zhang, H., Kong, B., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.670
Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends
Harindran, V. D., Sadanandan, V. P. S., Sreedath, P. V., Prashanth, P., Sajeevan, K. V., Sreedharan, P. S., & Warrier, N. E. (2022) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1742321
Targeted therapy and molecular genetics
Westin, S. N., Sood, A. K., & Coleman, R. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00024-6
Tratamiento médico de los cánceres epiteliales de ovario
Corbaux, P., Sajous, C., Péron, J., Bakrin, N., Bolze, P., Gléhen, O., Képénékian, V., Gertych, W., Philip, C., Chene, G., et al. (2022) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(22)47072-x
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
Burchell, C. (2018) · EMJ Oncology · doi:10.33590/emjoncol/10313985
[Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang, P., He, M., Zeng, Y., & Cai, X. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.01.02
Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2023) · doi:10.1158/1078-0432.c.6532290.v1
Self-citation
Data from Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
Färkkilä, A., Rodríguez, A., Oikkonen, J., Gulhan, D., Nguyen, H. Q., Domínguez-Soberanes, J., Ramos, S., Mills, C. E., Pérez‐Villatoro, F., Lazaro, J., et al. (2023) · doi:10.1158/0008-5472.c.6512719.v1
Self-citation
Data from EMT Transcription Factor ZEB1 Represses the Mutagenic POLθ-Mediated End-Joining Pathway in Breast Cancers
Prodhomme, M. K., Pommier, R. M., Franchet, C., Fauvet, F., Bergoglio, V., Brousset, P., Morel, A., Brunac, A., Devouassoux‐Shisheboran, M., Pétrilli, V., et al. (2023) · doi:10.1158/0008-5472.c.6513058.v1
Data from EMT Transcription Factor ZEB1 Represses the Mutagenic POLθ-Mediated End-Joining Pathway in Breast Cancers
Prodhomme, M. K., Pommier, R. M., Franchet, C., Fauvet, F., Bergoglio, V., Brousset, P., Morel, A., Brunac, A., Devouassoux‐Shisheboran, M., Pétrilli, V., et al. (2023) · doi:10.1158/0008-5472.c.6513058
Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236
Self-citation
Data from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Dai, W., Chung, D. L., Chow, L. K.-Y., Yu, V. Z., Lei, L. C., Leong, M. M., Chan, C. K.-C., Ko, J. M. Y., & Lung, M. L. (2023) · doi:10.1158/1078-0432.c.6529601
Data from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Dai, W., Chung, D. L., Chow, L. K.-Y., Yu, V. Z., Lei, L. C., Leong, M. M., Chan, C. K.-C., Ko, J. M. Y., & Lung, M. L. (2023) · doi:10.1158/1078-0432.c.6529601.v1
Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Serra, V., Wang, A. T., Castroviejo‐Bermejo, M., Polanska, U. M., Palafox, M., Herencia-Ropero, A., Jones, G. N., Lai, Z., Armenia, J., Michopoulos, F., et al. (2023) · doi:10.1158/1078-0432.c.6532931.v1
Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236.v1
Self-citation
Data from VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
Ekstrom, T. L., Pathoulas, N. M., Huehls, A. M., Kanakkanthara, A., & Karnitz, L. M. (2023) · doi:10.1158/1535-7163.c.6543424.v1
Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E. P., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2023) · doi:10.1158/2159-8290.c.6548069
The use of homologous recombination deficiency (HRD) scores in predicting the prognosis of ovarian cancerPreprint
Wu, Q., Huo, Y., Wu, J., Pan, C., Lu, C., Chen, L., & Zhang, F. (2023) · Research Square · doi:10.21203/rs.3.rs-3059241/v1
Gynecological Malignancies in Albania: The Challenges of Cancer Care in a Low Resource Country
Mati, K., Pozzo, C., Cekani, E., Qeraj, K., Prifti, J., Pecini, O., Elmasllari, A., Skoku, F., & Romagnolo, C. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5007139
Data from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Pérez‐Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., et al. (2023) · doi:10.1158/1078-0432.c.6533165.v2
Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine
Shikama, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-5231-1_5
Genomic instability as a predictive biomarker for the application of DNA-damaging therapies in gynecological cancer patients
Reig, R. L. (2023) · doi:10.4995/thesis/10251/199026
Homologous recombination deficiency reflects the heterogeneity and monitoring treatment response for patients with breast cancer
Long, Q., Wang, Y., & Li, H. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3637
Advances in the Medical Management of Ovarian Cancer
Pickwell‐Smith, B., Kayani, M., & Perren, T. J. (2023) · Essentials of Diagnostic Gynecological Pathology. · doi:10.1007/978-3-031-39659-5_15
TP53 Mutation Type and Platinum-Free Interval in Patients with High-Grade Serous Ovarian Cancer
Соколенко, А. П., Городнова, Т. В., Котив, Х. Б., Берлев, И. В., & Имянитов, Е. Н. (2024) · Voprosy Onkologii · doi:10.37469/0507-3758-2024-70-3-550-556
Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?
Ray-Coquard, I. L., Saux, O. L., Chopin, N., Rossi, L., Treilleux, I., Rousset‐Jablonski, C., Rebotier, M., Toussaint, P., Rannou, C., Buisson, A., et al. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.06.020
A 15-Gene prognostic signature with TFAP2B functioning in Platinum Resistance of Ovarian CarcinomaPreprint
Hu, Y., Wang, P., Xiang, J., Han, L., Zhang, B., Liu, X., Nie, H., Chen, G., & Qin, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.07.611781
A Risk Model Developed based on Homologous Recombination Deficiency Genes for Evaluating the Drug Sensitivity and Prognostic Prediction of Lung Adenocarcinoma
Hong, L., Li, J., & Shao, W. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673333745240927074414
Treatments Relevant to Individual Cancer Types
Vickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch7
More Targets and Treatments
Vickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch4
Optimal Prescriptive Treatments for Ovarian Cancer with Genetic DataPreprint
Mertzios, A., Gjika, M., Xu, X., Guha, S., Bardhan, N. M., Kumar, S., Belcher, A. M., & Perakis, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.08.617334
Differential expression of the SLC34A2 gene in different histological subtypes of ovarian carcinomas
Nurgalieva, A. K., Fetisov, T. I., Kuzin, K. A., Шакирова, Э. Ж., & Kiyamova, R. (2024) · Kazan medical journal · doi:10.17816/kmj632939
Incidence of homologous recombination deficiency among high grade serous ovarian carcinoma patients from a tertiary care center in India
Goswami, U., Ray, V., Ananthakrishnan, R., Jayaraman, K., Mohapatra, S., & Thirumalairaj, R. (2024) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20244126
Role of PARP inhibitors in ovarian cancer
Casado, A., Marrero, M., García, M., Cabello, A., & Marquina, G. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00100
The Oncology Team of The Karlovac General Hospital Was the First in Croatia To Perform Ovarian Cancer Surgery Using the Latest ICG Technology-Case Report
Tufeković, D. (2025) · Annals of Clinical Reviews & Case Reports · doi:10.71010/acrcr.2025-e140
Analysis of the Predictive Value of CA125 Elimination Rate Constant (KELIM) for Outcomes of Interval Debulking Surgery and Prognosis in High-Grade Serous Ovarian Cancer
Zeng, C., & Hu, Z. (2025) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres2066
BRCA-ASSOCIATED OVARIAN CANCER: EXPERIENCE PERSONALIZED TREATMENT. A CLINICAL CASE
Aidarov, A., Khaidarov, S., Kaidarova, D., Bolatbekova, R., Aidarov, D., Amankulov, J., Orazgaliyeva, M., & Ossikbayeva, S. (2025) · Oncologia i radiologia Kazakhstana · doi:10.52532/2521-6414-2025-1-75-419
Shedding LIGHT on the changing landscape of poly‐ADP ribose polymerase inhibitors in ovarian cancer
Frey, M. K., & Liu, J. F. (2025) · Cancer · doi:10.1002/cncr.35800
Mutational landscape of ovarian carcinomas: An Australian study of 116 patients
Robin, J., Djitro, N., Song, L., Pyrchla, P., Yuan, B., Htain, P., Goh, A. F. N., Lee, J. S., Quach, R., Krause, B., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155958
Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma
Xu, C., Xu, W., Wu, C., Chen, X., Ma, Z., Wang, J., Zhuo, Y., Cai, X., Zhang, Y., Lyu, Y., et al. (2025) · Human Cell · doi:10.1007/s13577-025-01253-4
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentPreprint
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J. S., Wang, Y., Wang, B., Shen, J., et al. (2025) · eLife · doi:10.7554/elife.99225.2
Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026)
Yoshihara, K., Tanigawa, T., Nishio, S., Kanao, H., Yoshino, Y., Mochizuki, A., Nakao, S., Kagimura, T., Tanabe, H., Kajiyama, H., et al. (2026) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2027.38.e5
RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer
Ota, Y., Elizagaray, M. L., Gupta, V., Fashemi, B., Akande, M., Babu, P., Thuthika, P. K., Lomonosova, E., Brill, J., Sun, L., et al. (2026) · JCI Insight · doi:10.1101/2025.09.24.678351 · Cited by 1
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentPreprint
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J. S., Wang, Y., Wang, B., Shen, J., et al. (2025) · eLife · doi:10.7554/elife.99225.3
Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report
Kawamura, M., Tada, H., Shirota, H., Dobashi, M., Takenaga, N., Yasojima, H., Harada‐Shoji, N., Komine, K., Nakamura, K., Miyashita, M., et al. (2025) · Cancer Science · doi:10.1111/cas.70210
Mechanisms Underlying the Resistance to Platinum and PARP Inhibitors in BRCA1/2-Mutated Tumors
Taniguchi, T. (2025) · Springer eBooks · doi:10.1007/978-981-96-6779-6_2
The Landscape of Personalized Medicine in Gynecologic Cancer
Foxall, M. E., & Arend, R. C. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.012
Surveying the Proteome-Wide Landscape of Mitoxantrone and Examining Drug Sensitivity in BRCA1-Deficient Ovarian Cancer Using Quantitative Proteomics
Wallin, S., Pandithar, S., Singh, S., Kumar, S., Natarajan, A., Borgstahl, G. E. O., & Woods, N. T. (2025) · Proteomes · doi:10.3390/proteomes13040061
Genetic variants in the homologous recombination pathway as common risk for premature ovarian insufficiency and ovarian cancer
Li, Y., Cao, Z., Gao, J., Xu, P., Gao, Y., He, L., Ji, W., Qin, Y., Hong, Y., Guo, T., et al. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.11.007
Towards antibody-based immunotherapy development for platinum-resistant high-grade serous ovarian cancer
Giedraityte, Z., Aarnio, N., Mohamed, F. A. N., Bjørge, L., & Meri, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-30099-x
m6A-Related SNPs in endometriosis and ovarian cancer: implications for chemoresistance and therapeutic targeting
Qiu, T., Ding, R., She, H. Q., Wang, X. Y., Xu, H., Yuan, L., Liang, M. S., Zou, X. X., & Huang, S. J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115894
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Corr, B. R., Woodruff, E. R., Yamamoto, T. M., Jordan, K. R., Danhorn, T., Bossard, C., Nguyen, L. L., Chuong, E. B., Wick, L., Young, A., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0267
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Lebeau, A., Kakkos, A., Leroi, N., Bours, V., Delbecque, K., Goffin, F., Gonne, E., & Gennigens, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251392106
The importance of the level of T-cell receptor excision circles and κ-deletion B-cell receptor excision circles in the effectiveness of therapy for metastatic ovarian cancer
Султанбаев, А. В., Тузанкина, И. А., Меньшиков, К. В., Насретдинов, А. Ф., Султанбаева, Н. И., Мусин, Ш. И., Измайлов, А. А., Султанбаев, М. В., Izmailova, A. A., Troshenkov, E. A., et al. (2025) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2025-24-4-31-38
Homologous Recombination Is Associated with Enhanced Anti-Tumor Innate Immunity and Favorable Prognosis in Head and Neck Cancer
Soghli, N., Khormali, A., & Peng, A. (2025) · Cancers · doi:10.3390/cancers17243999
Probabilistic modeling of cell cycle dynamics in response to cell cycle targeting chemotherapy drugs to guide treatment strategies
Ma, C., & Gürkan-Çavusoglu, E. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013790
Association of homologous recombination repair gene mutation with clinical prognosis in histological subtypes of epithelial ovarian cancer patients
Wang, Y.-H., Hsu, H., Lin, P., Kuo, K., Tai, Y., Wu, C., & Chiang, Y. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2026.37.e35
Metabolomics Plasma Biomarkers Associated with the HRD Phenotype in Ovarian Cancer
Tubita, A., Angelis, C. D., Grasso, D., Sorbi, F., Castiglione, F., Anela, L., Petrella, M. C., Fambrini, M., Scolari, F., Bernini, A., et al. (2025) · Metabolites · doi:10.3390/metabo16010002
Additional file 2 of Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
Roussel-Simonin, C., Blanc-Durand, F., Tang, R., Vasseur, D., Formal, A. L., Chardin, L., Yaniz‐Galende, E., Gouy, S., Maulard, A., Scherier, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26636166
Additional file 4 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486665
Additional file 1 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26061510
Additional file 1 of Germline variation of Ribonuclease H2 genes in ovarian cancer patients
Polaczek, R., Schürmann, P., Speith, L.-M., Geffers, R., Dürst, M., Hillemanns, P., Park-Simon, T.-W., Liebrich, C., & Dörk, T. (2020) · Figshare · doi:10.6084/m9.figshare.13481046
Additional file 1 of Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
Ma, Y., Liu, J., Li, N., Bu, H., Huang, Y., Jin, C., Wen, H., Feng, S., Zhang, H., Yang, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24452484
Additional file 3 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486662
Additional file 2 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26061556
Additional file 1 of CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Lu, X., He, Y., Johnston, R. L., Nanayakkara, D. M., Sankarasubramanian, S., Lopez, J. A., Friedlander, M. L., Kalimutho, M., Hooper, J. D., Raninga, P. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22598783
Additional file 2 of CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Lu, X., He, Y., Johnston, R. L., Nanayakkara, D. M., Sankarasubramanian, S., Lopez, J. A., Friedlander, M. L., Kalimutho, M., Hooper, J. D., Raninga, P. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22598786
Additional file 1 of The potential of PARP as a therapeutic target across pediatric solid malignancies
Keller, K. M., Koetsier, J., Schild, L. G., Amo-Addae, V., Eising, S., van den Handel, K., Ober, K., Koopmans, B., Essing, A. H. W., van den Boogaard, M. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26580593
Additional file 1 of LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer
Dey, G., Bharti, R., Braley, C., Alluri, R. K., Esakov, E. L., Crean-Tate, K., McCrae, K., Joehlin-Price, A. S., Rose, P. G., Lathia, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23590398
Additional file 1 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486656
Additional file 2 of Germline variation of Ribonuclease H2 genes in ovarian cancer patients
Polaczek, R., Schürmann, P., Speith, L.-M., Geffers, R., Dürst, M., Hillemanns, P., Park-Simon, T.-W., Liebrich, C., & Dörk, T. (2020) · Figshare · doi:10.6084/m9.figshare.13481049
Additional file 5 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26735955
Additional file 3 of Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Feng, Z., Шао, Д., Cai, Y., Bi, R., Ju, X., Chen, D., Song, C., Chen, X., Li, J., An, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22626073
Additional file 1 of A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
Liu, Y., Wang, W., Yin, R., Zhang, Y., Zhang, Y., Zhang, K., Pan, H., Wang, K., Lou, G., Li, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24223840
Additional file 2 of The potential of PARP as a therapeutic target across pediatric solid malignancies
Keller, K. M., Koetsier, J., Schild, L. G., Amo-Addae, V., Eising, S., van den Handel, K., Ober, K., Koopmans, B., Essing, A. H. W., van den Boogaard, M. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26580596
Additional file 2 of Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Feng, Z., Шао, Д., Cai, Y., Bi, R., Xingzhu, J., Chen, D., Song, C., Chen, X., Li, J., An, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22626070
Additional file 6 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26735958
Additional file 4 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26735952
Additional file 1 of Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Feng, Z., Шао, Д., Cai, Y., Bi, R., Ju, X., Chen, D., Song, C., Chen, X., Li, J., An, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22626067
Additional file 1 of GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing
Chen, D., Shao, M., Meng, P., Wang, C., Li, Q., Cai, Y., Song, C., Wang, X., & Shi, T. (2021) · Figshare · doi:10.6084/m9.figshare.17073489
Additional file 4 of Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Feng, Z., Шао, Д., Cai, Y., Bi, R., Xingzhu, J., Chen, D., Song, C., Chen, X., Li, J., An, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22626076
Additional file 1 of Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
Roussel-Simonin, C., Blanc-Durand, F., Tang, R., Vasseur, D., Formal, A. L., Chardin, L., Yaniz‐Galende, E., Gouy, S., Maulard, A., Scherier, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26636163
Additional file 1 of TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer
Zorea, J., Motro, Y., Mazor, R. D., Carmi, Y. K., Shulman, Z., Mahajna, J. A., Moran-Gilad, J., & Elkabets, M. (2024) · Figshare · doi:10.6084/m9.figshare.26586060
Additional file 3 of Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26735949
Interpreting Genomic Alterations to Understand Effectiveness and Adverse Reactions to Cancer Therapeutics: Insights from the Oncology Pharmacy Field
Rezaei, M., Karimi, A., Mohammadi, R., Jalali, S., & Farhadi, H. (2022) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/fuflrmnfnt
Deficiencies in germline DNA repair are associated with early-onset gastrointestinal cancers and inform precision prevention strategies
Yang, W., Zhang, Y., Ge, M., Liu, L., Shu, Y., Shen, D., Zhang, Q., Chen, D., Xu, P., & Liu, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07595-9
Functional And Clinical Significance Of The Hotaır–Mir-34a–CCND1 Axis İn Brca1-Mutated Ovarian Cancer
Özdemir, B. G., Bilgi, A., Celik, C., & Arikoglu, H. (2025) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1838216
Integrative Transcriptomic and Systems-Level Analysis Identifies GPCR- Related Biomarkers NTSR1 and GPR161 in Parkinson’s DiseasePreprint
Kumar, S. (2026) · Research Square · doi:10.21203/rs.3.rs-8404162/v1
Biología molecular del cáncer epitelial de ovario
Viveros-Carreño, D. A., Cruz-Castro, C., Fernándes, A., Bryon-Gallego, A., Martínez-Cruz, L., Mora‐Soto, N., Pareja, R., Agustí, N., & Pierre, M. E. (2026) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.839
Smart nanomaterials targeting spatially heterogeneous immunosuppressive niches to reverse ovarian cancer resistance and enhance immune checkpoint therapy
Han, X., Gao, M., Quan, Y., & Zhang, C. (2026) · Nano Research · doi:10.26599/nr.2026.94908631
Critical roles of Hedgehog signaling pathway in regulating the multidrug resistance of ovarian cancer
Bi, R., Dong, X., Cui, B., Dong, H., Liu, C., Chen, W., Liu, J., Liu, Y., Du, J., & Wang, F. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02065-2
A base editing resource for functional annotation of DNA repair variants in breast-derived cell models
Masud, W., Russo, L., Chapdelaine, V., Hayward, S. B., He, W., Cirò, M., Mercurio, C., Xu, H., Ciccia, A., Cuella-Martin, R., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1714494
日本人卵巣癌患者における相同組換え修復関連遺伝子の生殖細胞系列および体細胞変異
Sugino, K. (n.d.) · Institutional Repositories DataBase (IRDB)
Comprendre et perturber le choix de la voie de réparation des cassures double brin de l'ADN pour augmenter l'efficacité et la sélectivité des agents anticancéreux génotoxiques
Chanut, P. (2017) · theses.fr (ABES) · doi:10.70675/8712c9e0za693z4ff3zac1cz5973c1d276f9
Modulation des voies de réparation des cassures double-brin de l’ADN par ZEB1, un facteur de transcription impliqué dans l’EMT, dans le cancer du sein
Prodhomme, M. K. (2020) · theses.fr (ABES) · doi:10.70675/b91f7284z097fz467czb4d1ze6e33914f9d7
Validation de biomarqueurs prédictifs de la réponse au traitement : extension des courbes de prédictivités à un critère de jugement censuré
Mboup, B. (2020) · theses.fr (ABES) · doi:10.70675/f9e43816z32a2z48eez9ae4zb22feb940d3d

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks